Chiasma secures new funding to support Phase III oral octreotide programme
This article was originally published in Scrip
Executive Summary
Chiasma has closed $38.5 million in equity financing to fund the completion of Phase III development for Octreolin, the private company's proprietary oral form of the peptide octreotide for the treatment of acromegaly and neuroendocrine tumours.